Last updated: February 23, 2026
What is the market position of NORCO?
NORCO is a brand name for a combination analgesic containing hydrocodone and acetaminophen, commonly used for moderate to severe pain management. Once a leading opioid prescribed for pain, NORCO's market share has declined due to regulatory actions and the opioid crisis.
Market Overview
- Historical Market Share: NORCO was among the top prescribed opioids in the U.S. with over 20 million prescriptions annually before 2010.
- Decline: Post-2010, the market share of NORCO decreased sharply due to increased regulation and litigation against opioid manufacturers and distributors.
- Current Status: It is classified as a Schedule II controlled substance in the U.S., with prescriptions declining by approximately 40% from 2010 to 2022.
Key Market Drivers
- Regulation and Legislation: Stricter prescribing guidelines, including CDC guidelines in 2016, restrict opioid use.
- Legal Risks: Manufacturers face ongoing litigation, leading to product withdrawals.
- Alternative Therapies: Increased adoption of non-opioid pain treatments reduces demand.
- Pandemic Impact: COVID-19 slowed healthcare visits, temporarily decreasing prescriptions further.
How have regulatory policies affected NORCO's market?
- FDA Warnings: The FDA issued boxed warnings and requested label changes to limit misuse and overdose risks.
- DEA Scheduling: Hydrocodone combined products reclassified from Schedule III to Schedule II in 2014, increasing prescribing restrictions.
- Legal Actions: Purdue Pharma, the primary manufacturer of NORCO, faced over 2,000 opioid-related lawsuits, prompting settlements and product discontinuations.
What is the financial trajectory for NORCO?
Revenue Trends
| Year |
U.S. Prescriptions |
Estimated Market Revenue (USD millions) |
Change from Prior Year |
| 2010 |
20 million |
2,500 |
— |
| 2015 |
12 million |
1,500 |
-40% |
| 2020 |
8 million |
1,000 |
-33% |
| 2022 |
6 million |
750 |
-25% |
Note: Revenue includes both brand and generic formulations, with generics accounting for approximately 70%.
Key Factors Impacting Financials
- Patent and Formulation Changes: Patent expirations and the shift to generics led to price erosion.
- Manufacturing and Litigation Costs: Legal settlements and manufacturing adjustments impact profit margins.
- Market Shift: Growing preference for non-opioid alternatives, such as NSAIDs and nerve pain treatments, reduces overall revenue potential.
- Withdrawal from Markets: Some manufacturers have withdrawn NORCO products in response to legal and regulatory pressures.
How does the competitive landscape look?
- Generic Market Dominance: Generics account for the majority of prescriptions, reducing brand value.
- Emerging Alternatives: Non-opioid analgesics like tramadol, gabapentin, and topical treatments expand options.
- Legal and Social Risks: Potential liabilities and changing societal attitudes toward opioids limit future growth.
What are the strategic outlooks?
- Market Contraction: Expect further decline in prescriptions and revenue within the next 2-5 years.
- Product Discontinuation: Several manufacturers have removed NORCO components from the market.
- Regulatory Environment: Future policies likely to tighten restrictions, affecting supply and profitability.
- Pipeline Developments: Consideration of alternative formulations, such as abuse-deterrent technologies, though adoption remains limited.
Key Takeaways
- NORCO experienced significant market share decline due to regulation, litigation, and evolving prescribing practices.
- Revenue has contracted by approximately 70% since 2010, with ongoing downward trends expected.
- The landscape has shifted toward generics and non-opioid therapies, reducing profitability.
- Legal risks and societal pressures hinder market recovery prospects.
- Industry participants are focusing on abuse-deterrent formulations and non-opioid alternatives to sustain revenue streams.
FAQs
Q1: Will NORCO return to higher prescription levels?
A1: Unlikely. Regulatory, legal, and societal barriers suppress future growth.
Q2: Are generic versions still available?
A2: Yes, generics dominate the market; prescriptions for hydrocodone/acetaminophen formulations still exist but in declining numbers.
Q3: What legal risks impact NORCO's market?
A3: Manufacturers face lawsuits related to opioid misuse and overdose, prompting product withdrawals and settlements.
Q4: How have recent policies affected opioid-based therapies?
A4: Policies restrict prescribing, introduce abuse-deterrent technologies, and promote alternative pain management strategies.
Q5: What is the outlook for stakeholders involved with NORCO?
A5: Investors and manufacturers should expect declining revenues, increased regulatory costs, and a shift toward non-opioid pain therapies.
References
[1] CDC. (2016). Guideline for prescribing opioids for chronic pain. Centers for Disease Control and Prevention.
[2] FDA. (2021). Safety communication on opioids. Food and Drug Administration.
[3] IMS Health. (2022). U.S. prescription data report.
[4] Purdue Pharma. (2022). Litigation and settlement updates.
[5] U.S. Drug Enforcement Administration. (2014). Rescheduling of hydrocodone products.
